RNAseq analysis of integrin β3-mediated responses to in vitro docetaxel in PyMT-BO1 breast cancer cells

We sought to transcriptomically characterize the effect of integrin β3 expression on breast cancer cell responses to the microtubule-inhibiting chemotherapeutic agent docetaxel. Experiments were performed in PyMT-BO1 murine breast cancer cells with CRISPR mediated deletion of the Itgb3 gene. Cells were subsequently retrovirally rescued using either an empty vector construct (pMx), a functional human integrin β3 construct (hβ3), or a signaling-deficient integrin β3 mutant. mRNA profiles from β3KO PyMT-BO1 murine breast cancer cells rescued with empty vector (pMx), functional integrin β3 (hβ3), or signaling-deficient mutant integrin β3 (Δβ3) and receiving 24 hours of treatment with either DMSO or 10nM docetaxel. 3 biological replicates per treatment group.